"Nov. 2, 2012 -- Safety steps taken in the wake of the fungal meningitis outbreak have worsened drug shortages, raising questions about whether the U.S. must choose between the safety and the availability of crucial medicines.
Qutenza Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Qutenza (capsaicin) 8% Patch is a manmade version of a naturally occurring compound found in chili peppers used to manage neuropathic pain associated with postherpetic neuralgia (nerve pain following an outbreak of shingles). Common side effects of Qutenza Patch include application site reactions (pain, redness, itching, swelling, burning, dryness, rash or bumps), increased blood pressure, runny or stuffy nose, sore throat, cough, nausea, or vomiting.
The recommended dose of Qutenza is a single, 60-minute application of up to four patches. Treatment may be repeated every three months or as warranted by the return of pain (not more frequently than every three months). Qutenza is only administered under the close supervision of a physician. Qutenza may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Qutenza. It is unknown if this drug passes into breast milk. Mothers can reduce infant exposure by not breastfeeding after treatment on the day of treatment. Consult your doctor before breastfeeding.
Our Qutenza (capsaicin) 8% Patch Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Qutenza FDA Prescribing Information: Side Effects
The following serious adverse reactions are discussed elsewhere in the labeling:
- Application-Associated Pain [see WARNINGS AND PRECAUTIONS]
- Increase in Blood Pressure [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in clinical practice.
Across all controlled and uncontrolled trials, more than 1,600 patients have received Qutenza. A total of 394 patients received more than one treatment application and 274 patients were followed for 48 weeks or longer.
In controlled clinical studies, 98% of patients completed ≥ 90% of the intended patch application duration. Among patients treated with Qutenza, 1% discontinued prematurely due to an adverse event.
Controlled Clinical Studies
Common Adverse Reactions
Adverse reactions occurring in ≥ 5% of patients in the Qutenza group and at an incidence greater than in the control group were application site erythema, application site pain, application site pruritus and application site papules.
Table 1 summarizes all adverse reactions, regardless of causality, occurring in ≥ 1% of patients with postherpetic neuralgia in the Qutenza group for which the incidence was greater than in the control group. The majority of application site reactions were transient and self-limited. Transient increases in pain were commonly observed on the day of treatment in patients treated with Qutenza. Pain increases occurring during patch application usually began to resolve after patch removal. On average, pain scores returned to baseline by the end of the treatment day and then remained at or below baseline levels. A majority of Qutenza-treated patients in clinical studies had adverse reactions with a maximum intensity of “mild” or “moderate”.
TABLE 1: Treatment-emergent adverse reaction incidence
(%) in controlled trials in Postherpetic Neuralgia (Events in ≥ 1% of
Qutenza-treated patients and at least 1% greater in the Qutenza group than in
the Control group)
|Body System Preferred Term||Qutenza 60 minutes
(N = 622) %
|Control 60 minutes
(N = 495) %
|General Disorders and Administration Site Conditions|
|Application Site Erythema||63||54|
|Application Site Pain||42||21|
|Application Site Pruritus||6||4|
|Application Site Papules||6||3|
|Application Site Edema||4||1|
|Application Site Swelling||2||1|
|Application Site Dryness||2||1|
|Infections and Infestations|
|Skin and Subcutaneous Tissue Disorder|
Other Adverse Reactions Observed During the Clinical Studies of Qutenza
General Disorders and Administration Site Conditions: Application site urticaria, Application site paresthesia, Application site dermatitis, Application site hyperesthesia, Application site excoriation, Application site warmth, Application site anesthesia, Application site bruising, Application site inflammation, Application site exfoliation, Peripheral edema
Nervous System Disorders: Headache, Burning sensation, Peripheral sensory neuropathy, Dizziness, Dysgeusia, Hyperesthesia, Hypoesthesia
Respiratory, Thoracic and Mediastinal Disorders: Cough, Throat irritation
Skin and Subcutaneous Tissue Disorders: Abnormal skin odor
Read the entire FDA prescribing information for Qutenza (Capsaicin 8% Patch)
Additional Qutenza Information
Report Problems to the Food and Drug Administration
Chronic Pain/Back Pain
Find tips and advances in treatment.